
    
      This is a Phase 1b/2a, randomized, multi-center, open-label study. Twenty otherwise healthy
      subjects with functioning ileostomies who are between the ages of 18 and 80 years, inclusive,
      will be enrolled. The entire duration of the study may be up to 63 days (from Screening to
      the end-of-study [EOS] visit).
    
  